Out of 56 patients with minor mutations of the EGFR gene, 44 were treated with either gefitinib or erlotinib. Mutation sites were G719X in exon 18 (n=35), L861Q in exon 21 (n=11), and G874S in exon 21 (n=1). Three patients had both the G719S and the L861Q mutation...The median PFS for all 44 patients was 6.70 months [95% confidence interval (CI)=2.06-8.66 months], with a longer median PFS for those treated with erlotinib than gefitinib (7.50 versus 5.83 months; log-rank p=0.32) (Figure 2)….Treatment with first-generation EGFR-TKIs, in particular erlotinib, may be considered a first- or second-line option for patients with NSCLC with minor EGFR mutations.